The very low expression of HSF1 in normal human BMs compared to diffuse positivity of nuclear HSF1 in AML BMs, regardless of CD34 positivity (Fig. 6e), suggests that HSF1 may be more useful than CD34 for monitoring malignant status in AML. This evidence concerns the gene CD34 and acute myeloid leukemia.